Home Tags Datroway®

Tag: Datroway®

ESMO 2026: ADC Developments Across Solid Tumors—Emerging Efficacy, Treatment Sequencing, and...

Antibody–drug conjugates (ADCs) are moving from late-line salvage therapy into first-line combinations, maintenance strategies, and planned treatment sequences. Abstracts presented at the ESMO Congress 2026 in Madrid describe how clinicians currently choose among ADCs, how much activity is lost when one ADC follows another, and whether functional testing can add to conventional biomarkers. Read alongside recent work on resistance biology and new ADC formats, these studies point to one practical conclusion: ADC choice increasingly depends on what kind of therapy the patient has already received, not only on the antigen the tumor expresses.
Daiichi Sankyo

Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC...

Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible for Immunotherapy

US FDA Approved Datopotamab Deruxtecan as first TROP2 Directed Therapy for...

Datopotamab deruxtecan (datopotamab deruxtecan-dlnk in the U.S. only; Datroway®; Daiichi Sankyo and AstraZeneca; see ADC Drug Map) has been approved by the U.S. Food and Drug Administration (FDA)

US FDA Grants Breakthrough Device Designation for first AI-driven Companion Diagnostic...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the VENTANA® TROP2 (EPR20043) RxDx Device. This is the first Breakthrough Device Designation to be granted for a computational pathology companion diagnostic (CDx) device.

Phase 3 TROPION-Lung12 Study Evaluates Datopotamab Deruxtecan as Part of Adjuvant...

A first patient has been dosed in the TROPION-Lung12 phase 3 trial (NCT06564844), a global, multicenter, three-arm, open-label phase 3 trial designed to evaluate the efficacy and safety of adjuvant datopotamab deruxtecan (6 mg/kg; Datroway®; Daiichi Sankyo and AstraZeneca; see: ADC Drug Map) in combination with the PD-1/TIGIT bi-specific antibody rilvegostomig* (750 mg) or rilvegostomig monotherapy (750 mg) monotherapy versus observation or standard of care adjuvant chemotherapy regimens.

Datopotamab deruxtecan Approved in the USA

Datopotamab deruxtecan (Datroway®; Daiichi Sankyo and AstraZeneca; see: ADC Drug Map) has been approved by the US Food and Drug Administration for the treatment of adult patients...
Featured Image: Women and the power to fight breast cancer Courtesy: © 2017. Fotolia. Used with permission.

Japan Approves Datopotamab Deruxtecan for the Treatment of Adult Patients with...

Datopotamab deruxtecan (Datroway®; Daiichi Sankyo, previously known as DS-1062 and TROP2 ADC, see ADC Drug Map) an antibody-drug conjugate or ADC, being jointly developed and commercialized globally by Daiichi Sankyo and AstraZeneca, has been approved in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) unresectable or recurrent breast cancer after prior chemotherapy.